Biogen
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: GSK1014802Drug: Placebo
- First Posted Date
- 2009-08-10
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 60
- Registration Number
- NCT00955396
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe
Phase 3
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Interferon beta-1aDevice: Single-use autoinjector
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2009-06-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 74
- Registration Number
- NCT00915577
Open-Label Safety Extension Study of Avonex
Phase 4
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Interferon beta-1a (Avonex)
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2009-06-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 408
- Registration Number
- NCT00915460
Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers
Phase 4
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Interferon beta-1a (Avonex)
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2009-06-04
- Lead Sponsor
- Biogen
- Target Recruit Count
- 121
- Registration Number
- NCT00913666
A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers
Phase 1
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2009-06-04
- Lead Sponsor
- Biogen
- Target Recruit Count
- 96
- Registration Number
- NCT00913250
Immunogenicity and Safety Study of Serum-Free Avonex
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2009-06-10
- Lead Sponsor
- Biogen
- Target Recruit Count
- 155
- Registration Number
- NCT00912860
Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.
Phase 1
Completed
- Conditions
- Bipolar DepressionBipolar Disorder
- Interventions
- Drug: PlaceboDrug: GSK1014802
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- Biogen
- Target Recruit Count
- 51
- Registration Number
- NCT00908154
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis
Phase 3
Completed
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Drug: BIIB017 (peginterferon beta-1a)Drug: Placebo
- First Posted Date
- 2009-05-21
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1516
- Registration Number
- NCT00906399
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS
Completed
- Conditions
- Relapsing-Remitting Multiple SclerosisFatigue
- Interventions
- Other: Natalizumab
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 195
- Registration Number
- NCT00884481
- Locations
- 🇸🇪
Research Site, Örebro, Sweden
A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
Phase 4
Completed
- Conditions
- Relapsing Remitting Multiple Sclerosis (RRMS)
- Interventions
- Drug: BG00002 (natalizumab)
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 224
- Registration Number
- NCT00871780
- Locations
- 🇺🇦
Biogen Idec Investigative Site, Simferopol, Ukraine
© Copyright 2025. All Rights Reserved by MedPath